Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: With special emphasis upon visual safety

Current Opinion in Ophthalmology

Volumn 22, Issue 6, 2011, Pages 445-450

  Huggins, Alison ^a   Sergott, Robert C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA1A INTERFERON; CALCIUM CHANNEL BLOCKING AGENT; FINGOLIMOD; PLACEBO; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ATRIOVENTRICULAR BLOCK; BACKACHE; BLOOD PRESSURE MONITORING; BRADYCARDIA; BRONCHITIS; CONSULTATION; CORTICOSTEROID THERAPY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISABILITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFLUENZA; LUMBAR PUNCTURE; LUNG CAPACITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SKIN CANCER; SYSTOLIC BLOOD PRESSURE; VACCINATION; VARICELLA ZOSTER VIRUS; EDITORIAL; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; TREATMENT OUTCOME;

EID: 80054915750     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834be03b     Document Type: Review

References (6)

1. Gilenya (fingolimod) capsules (prescribing information). East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2010.
2. Chun J, Hartung H-P. Mechanism of action of oral fingolimod [FTY70] in multiple sclerosis. Clin Neuropharmacol 2010; 33:91-101.
3. Kappos L, Radue E-W, O'Connor P, et al., for the FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387-401.
4. Cohen JA, Barkof F, Comi G, et al., for the TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402-415.
5. Ucceli A, Ginocchio F, Mancardi GL, et al. Primary varicella zoster infection associated with fingolimod treatment. Neurology 2011; 76:1023.
6. Izquierdo G, O'Connor P, Montalban X, et al. Long-term fingolimod [FTY720] in relapsing MS: 5-year results from an extension of phase II multicenter study show a sustained low level of disease activity. Presented in poster form at the American Academy of Neurology Meeting; 2011.